Recent Analysts’ Ratings Updates for Disc Medicine (IRON)

Disc Medicine (NASDAQ: IRON) recently received a number of ratings updates from brokerages and research firms:

• 11/6/2026 – Disc Medicine had its price target raised by HC Wainwright from $120.00 to $127.00. They now have a “buy” rating on the stock.
• 10/21/2026 – Disc Medicine had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $149.00 price target on the stock.
• 10/20/2026 – Disc Medicine had its price target raised by Morgan Stanley from $90.00 to $92.00. They now have an “overweight” rating on the stock.
• 10/20/2026 – Disc Medicine had its price target raised by Wells Fargo & Company from $86.00 to $124.00. They now have an “overweight” rating on the stock.
• 10/19/2026 – Disc Medicine had its price target raised by Truist Financial from $83.00 to $115.00. They now have a “buy” rating on the stock.
• 10/19/2026 – Disc Medicine had its price target raised by BMO Capital Markets from $100.00 to $120.00. They now have an “outperform” rating on the stock.
• 10/19/2026 – Disc Medicine had its price target raised by Wedbush from $100.00 to $110.00. They now have an “outperform” rating on the stock.
• 10/19/2026 – Disc Medicine had its price target raised by Cantor Fitzgerald from $125.00 to $170.00. They now have an “overweight” rating on the stock.
• 10/17/2026 – Disc Medicine was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/15/2026 – Disc Medicine had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/16/2026 – Disc Medicine had its price target raised by Wells Fargo & Company from $79.00 to $86.00. They now have an “overweight” rating on the stock.
• 9/12/2026 – Disc Medicine was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/10/2026 – Disc Medicine had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.
• 9/10/2026 – Disc Medicine had its “outperform” rating reaffirmed by BMO Capital Markets.
• 9/10/2026 – Disc Medicine had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $128.00 price target on the stock.
• 9/10/2026 – Disc Medicine had its “outperform” rating reaffirmed by Wedbush. They now have a $100.00 price target on the stock.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON traded up $0.44 on Friday, reaching $78.91. 717,525 shares of the company’s stock were exchanged, compared to its average volume of 671,756. Disc Medicine, Inc. has a twelve month low of $40.00 and a twelve month high of $99.50. The company has a fifty day moving average of $71.28 and a 200-day moving average of $70.91. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of -11.99 and a beta of 0.96. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Thursday, November 5th. The company reported ($1.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.10. On average, research analysts predict that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Insider Buying and Selling at Disc Medicine

In other news, CEO John Quisel sold 33,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the completion of the sale, the chief executive officer directly owned 226,064 shares in the company, valued at approximately $17,892,965.60. This represents a 12.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Jonathan Yu sold 8,796 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $4,515,410.88. This represents a 13.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 168,046 shares of company stock valued at $13,191,034 in the last three months. Corporate insiders own 3.76% of the company’s stock.

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.